Full-Time
Develops analytical instruments for scientific research
No salary listed
Bellheim, Germany
In Person
Find people who can refer or advise you
Bruker Corporation provides analytical and diagnostic instruments used in life sciences, materials science, and environmental analysis. Its product lines include technologies such as nuclear magnetic resonance (NMR), mass spectrometry, imaging, and spectroscopy, which help researchers analyze the composition, structure, and properties of samples. These instruments work by measuring physical signals (like magnetic resonance, ion fragmentation patterns, or spectral fingerprints) from samples and translating them into data and insights via specialized software and workflows. Bruker differentiates itself through a long history of NMR expertise since 1960, a broad, integrated portfolio of measurement platforms, and a global footprint that supports researchers from development to routine analysis. Its goal is to empower scientists and industry professionals to advance research and solve real-world problems by providing reliable analytical tools and solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Billerica, Massachusetts
Founded
1960
Find people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Disability Insurance
Life Insurance
Dental Insurance
Flexible Work Hours
Employee Discounts
US life sciences company Bruker has acquired the DISQVER platform and selected assets of insolvent German diagnostics startup Noscendo through a restructuring sale. Financial terms were not disclosed. Duisburg-based Noscendo, founded in 2016, developed a method for identifying pathogens in under 24 hours using next-generation sequencing from cell-free DNA. The technology is used by university hospitals for sepsis diagnostics. Despite raising nearly €40 million in venture capital, commercialisation proceeded slower than expected due to delays in selective contracts and economic pressure on hospitals. A planned financing round with existing investors failed in February 2026, leading to insolvency proceedings in March. Insolvency administrator Sarah Wolf from Anchor Rechtsanwälte said the restructuring preserved the technology's value for creditors and partners. Bruker acquired the patent-protected software, intellectual property rights, and select IT and sales staff in Duisburg. The laboratory in Kusterdingen was partially closed in April.